Oridonin inhibits the proliferation of human colon cancer cells by upregulating BMP7 to activate p38 MAPK

Ren,Chun-Mei; Li,Yang; Chen,Qian-Zhao; Zeng,Yu-Hua; Shao,Ying; Wu,Qiu-Xiang; Yuan,Shuang-Xue; Yang,Jun-Qin; Yu,Yu; Wu,Ke; He,Bai-Cheng; Sun,Wen-Juan

doi:10.3892/or.2016.4654

Oridonin inhibits the proliferation of human colon cancer cells by upregulating BMP7 to activate p38 MAPK

Authors:
- Chun-Mei Ren
- Yang Li
- Qian-Zhao Chen
- Yu-Hua Zeng
- Ying Shao
- Qiu-Xiang Wu
- Shuang-Xue Yuan
- Jun-Qin Yang
- Yu Yu
- Ke Wu
- Bai-Cheng He
- Wen-Juan Sun
View Affiliations

Affiliations: Chongqing Municipal Key Laboratory of Higher Education Institutions for Biochemistry and Molecular Pharmacology, School of Pharmacy, Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China
Published online on: March 7, 2016 https://doi.org/10.3892/or.2016.4654
Pages: 2691-2698

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oridonin (ORI), a diterpenoid purified from Rabdosia rubescens, has been reported as a promising chemotherapy drug for colon cancer treatment; yet, the precise mechanisms underlying this anticancer activity remain unclear. In the present study, we investigated the anticancer effect of ORI in HCT116 cells, and dissected the possible molecular mechanisms underlying this activity. With crystal violet staining, flow cytometry and western blot assay, we found that ORI effectively inhibited the proliferation and induced the apoptosis of HCT116 cells. Further analysis of the results indicated that BMP7 was greatly upregulated by ORI in the HCT116 cells, but its endogenous expression in FHC cells was apparently lower than that in the colon cancer cell lines. Exogenous expression of BMP7 inhibited the proliferation of the HCT116 cells, and substantially potentiated the anticancer effect of ORI. However, the specific antibody of BMP7 nearly abolished this anticancer activity of ORI in the HCT116 cells. Meanwhile, ORI exerted no significant effect on the level of phosphorylated Smad1/5/8 or total p38 MAPK, but greatly increased the level of phosphorylated p38 MAPK in the HCT116 cells. A p38 MAPK-specific inhibitor partly reversed the antiproliferative effect of BMP7 in the HCT116 cells, but prominently promoted the effect of the BMP7 antibody on proliferation. Exogenous expression of BMP7 increased the ORI-induced phosphorylation of p38 MAPK, while the BMP7 antibody almost abolished the ORI-elevated p38 MAPK phosphorylation. Our findings suggest that ORI may be an efficacious drug for colon cancer treatment. This anticancer activity of ORI may be mediated by upregulating BMP7 at least to increase the activation of p38 MAPK.

View Figures

View References

1	Applegate CC and Lane MA: Role of retinoids in the prevention and treatment of colorectal cancer. World J Gastrointest Oncol. 7:184–203. 2015.PubMed/NCBI
2	Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
3	Banjerdpongchai R, Chanwikruy Y, Rattanapanone V and Sripanidkulchai B: Induction of apoptosis in the human leukemic U937 cell line by Kaempferia parviflora Wall.ex.Baker extract and effects of paclitaxel and camptothecin. Asian Pac J Cancer Prev. 10:1137–1140. 2009.PubMed/NCBI
4	Weaver BA: How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
5	Owona BA and Schluesener HJ: Molecular insight in the multifunctional effects of oridonin. Drugs R D. 15:233–244. 2015. View Article : Google Scholar : PubMed/NCBI
6	Liu Y, Liu YZ, Zhang RX, Wang X, Meng ZJ, Huang J, Wu K, Luo JY, Zuo GW, Chen L, et al: Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Int J Oncol. 45:795–803. 2014.PubMed/NCBI
7	Voorneveld PW, Kodach LL, Jacobs RJ, Liv N, Zonnevylle AC, Hoogenboom JP, Biemond I, Verspaget HW, Hommes DW, de Rooij K, et al: Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology. 147:196–208.e13. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bertrand FE, Angus CW, Partis WJ and Sigounas G: Developmental pathways in colon cancer: Crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle. 11:4344–4351. 2012. View Article : Google Scholar : PubMed/NCBI
9	Beck SE, Jung BH, Fiorino A, Gomez J, Rosario ED, Cabrera BL, Huang SC, Chow JY and Carethers JM: Bone morphogenetic protein signaling and growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol. 291:G135–G145. 2006. View Article : Google Scholar : PubMed/NCBI
10	Zhang Y, Chen X, Qiao M, Zhang BQ, Wang N, Zhang Z, Liao Z, Zeng L, Deng Y, Deng F, et al: Bone morphogenetic protein 2 inhibits the proliferation and growth of human colorectal cancer cells. Oncol Rep. 32:1013–1020. 2014.PubMed/NCBI
11	Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, de Maria R and Stassi G: Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology. 140:297–309. 2011. View Article : Google Scholar
12	Kamiya N, Ye L, Kobayashi T, Lucas DJ, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ and Mishina Y: Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res. 23:2007–2017. 2008. View Article : Google Scholar : PubMed/NCBI
13	Richard D and Picard F: Brown fat biology and thermogenesis. Front Biosci. 16:1233–1260. 2011. View Article : Google Scholar
14	Grijelmo C, Rodrigue C, Svrcek M, Bruyneel E, Hendrix A, de Wever O and Gespach C: Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal. 19:1722–1732. 2007. View Article : Google Scholar : PubMed/NCBI
15	Tormos AM, Taléns-Visconti R, Nebreda AR and Sastre J: p38 MAPK: A dual role in hepatocyte proliferation through reactive oxygen species. Free Radic Res. 47:905–916. 2013. View Article : Google Scholar : PubMed/NCBI
16	Bu HQ, Liu DL, Wei WT, Chen L, Huang H, Li Y and Cui JH: Oridonin induces apoptosis in SW1990 pancreatic cancer cells via p53- and caspase-dependent induction of p38 MAPK. Oncol Rep. 31:975–982. 2014.
17	Bu HQ, Luo J, Chen H, Zhang JH, Li HH, Guo HC, Wang ZH and Lin SZ: Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. Int J Oncol. 41:949–958. 2012.PubMed/NCBI
18	Guan J, Li H, Lv T, Chen D, Yuan Y and Qu S: Bone morphogenic protein-7 contributes to cerebral ischemic preconditioning induced-ischemic tolerance by activating p38 mitogen-activated protein kinase signaling pathway. Inflammation. 37:1289–1296. 2014. View Article : Google Scholar : PubMed/NCBI
19	Takahashi M, Otsuka F, Miyoshi T, Otani H, Goto J, Yamashita M, Ogura T, Makino H and Doihara H: Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. J Endocrinol. 199:445–455. 2008. View Article : Google Scholar : PubMed/NCBI
20	Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, et al: A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
21	Mishra L, Shetty K, Tang Y, Stuart A and Byers SW: The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene. 24:5775–5789. 2005. View Article : Google Scholar : PubMed/NCBI
22	Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S and Ikejima T: Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells. Biol Pharm Bull. 29:1873–1879. 2006. View Article : Google Scholar : PubMed/NCBI
23	Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: Differential control of growth, cell cycle progression, and expression of NF-κB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the Chinese herb Rabdosia rubescens. Biochem Biophys Res Commun. 337:224–231. 2005. View Article : Google Scholar : PubMed/NCBI
24	Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, et al: Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood. 109:3441–3450. 2007. View Article : Google Scholar : PubMed/NCBI
25	Zhu Y, Xie L, Chen G, Wang H and Zhang R: Effects of oridonin on proliferation of HT29 human colon carcinoma cell lines both in vitro and in vivo in mice. Pharmazie. 62:439–444. 2007.PubMed/NCBI
26	Li D, Wu LJ, Tashiro S, Onodera S and Ikejima T: Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/ERK signal pathway. J Pharmacol Sci. 103:56–66. 2007. View Article : Google Scholar : PubMed/NCBI
27	Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM, Ren Z, Li XM, Shen HM and Zeng HT: Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin. 28:1819–1826. 2007. View Article : Google Scholar : PubMed/NCBI
28	Gao FH, Liu F, Wei W, Liu LB, Xu MH, Guo ZY, Li W, Jiang B and Wu YL: Oridonin induces apoptosis and senescence by increasing hydrogen peroxide and glutathione depletion in colorectal cancer cells. Int J Mol Med. 29:649–655. 2012.PubMed/NCBI
29	Markowitz SD and Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
30	Saini S, Duraisamy AJ, Bayen S, Vats P and Singh SB: Role of BMP7 in appetite regulation, adipogenesis, and energy expenditure. Endocrine. 48:405–409. 2015. View Article : Google Scholar
31	Kuzaka B, Janiak M, Włodarski KH, Radziszewski P and Włodarski PK: Expression of bone morphogenetic protein-2 and -7 in urinary bladder cancer predicts time to tumor recurrence. Arch Med Sci. 11:378–384. 2015. View Article : Google Scholar : PubMed/NCBI
32	Li W, Cai HX, Ge XM, Li K, Xu WD and Shi WH: Prognostic significance of BMP7 as an oncogene in hepatocellular carcinoma. Tumour Biol. 34:669–674. 2013. View Article : Google Scholar
33	Aoki M, Ishigami S, Uenosono Y, Arigami T, Uchikado Y, Kita Y, Kurahara H, Matsumoto M, Ueno S and Natsugoe S: Expression of BMP-7 in human gastric cancer and its clinical significance. Br J Cancer. 104:714–718. 2011. View Article : Google Scholar : PubMed/NCBI
34	Liu Y, Chen J, Yang Y, Zhang L and Jiang WG: Molecular impact of bone morphogenetic protein 7, on lung cancer cells and its clinical significance. Int J Mol Med. 29:1016–1024. 2012.PubMed/NCBI
35	Alarmo EL, Pärssinen J, Ketolainen JM, Savinainen K, Karhu R and Kallioniemi A: BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett. 275:35–43. 2009. View Article : Google Scholar
36	Ying X, Sun Y and He P: Bone morphogenetic protein-7 inhibits EMT-associated genes in breast cancer. Cell Physiol Biochem. 37:1271–1278. 2015. View Article : Google Scholar : PubMed/NCBI
37	Lim M, Chuong CM and Roy-Burman P: PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures. Horm Cancer. 2:298–309. 2011. View Article : Google Scholar : PubMed/NCBI
38	Motoyama K, Tanaka F, Kosaka Y, Mimori K, Uetake H, Inoue H, Sugihara K and Mori M: Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol. 15:1530–1537. 2008. View Article : Google Scholar : PubMed/NCBI
39	Camara-Clayette V, Koscielny S, Roux S, Lamy T, Bosq J, Bernard M, Fest T, Lazar V, Lenoir G and Ribrag V: BMP7 expression correlates with secondary drug resistance in mantle cell lymphoma. PLoS One. 8:e739932013. View Article : Google Scholar : PubMed/NCBI
40	Fiaschetti G, Castelletti D, Zoller S, Schramm A, Schroeder C, Nagaishi M, Stearns D, Mittelbronn M, Eggert A, Westermann F, et al: Bone morphogenetic protein-7 is a MYC target with prosur-vival functions in childhood medulloblastoma. Oncogene. 30:2823–2835. 2011. View Article : Google Scholar : PubMed/NCBI
41	Itoh F, Asao H, Sugamura K, Heldin CH, ten Dijke P and Itoh S: Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J. 20:4132–4142. 2001. View Article : Google Scholar : PubMed/NCBI
42	Greenblatt MB, Kim JM, Oh H, Park KH, Choo MK, Sano Y, Tye CE, Skobe Z, Davis RJ, Park JM, et al: p38α MAPK is required for tooth morphogenesis and enamel secretion. J Biol Chem. 290:284–295. 2015. View Article : Google Scholar :